PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Calcitonin Salmon — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Salmon calcitonin has been used therapeutically for more than 30 years in metabolic bone diseases such as osteoporosis and Paget's disease. · pmid:18071651

History

In the five-year PROOF trial of 1,255 postmenopausal women with osteoporosis, the 200 IU nasal spray reduced new vertebral fractures by 33% versus placebo, while the 100 and 400 IU arms did not differ significantly from placebo. · pmid:10996576

Identity

PubChem CID 16220016: Calcitonin Salmon, C145H240N44O48S2, 3431.9 g/mol. · pubchem:16220016

CAS registry number 47931-85-1. · pubchem:16220016

Where the evidence actually sits

Established100%

Proportion of the 2 claims about Calcitonin Salmon standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. (2000) · establishedSalmon calcitonin: a review of current and future therapeutic indications. (2008) · established20002008

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Calcitonin Salmon yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. · pmid 10996576 · 2000
    • Salmon calcitonin: a review of current and future therapeutic indications. · pmid 18071651 · 2008
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.